Last reviewed · How we verify
CHF 5259 12.5 µg
At a glance
| Generic name | CHF 5259 12.5 µg |
|---|---|
| Also known as | glycopyrrolate bromide |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease (PHASE2)
- Efficacy of LAMA Added to ICS in Treatment of Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |